• 1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 2. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

The Synthesis, Properties, and Applications of 3,5-Difluoro-2-hydroxybenzonitrile (CAS No. 862088-17-3)

3,5-Difluoro-2-hydroxybenzonitrile, identified by CAS No. 862088-17-3, is a structurally unique aromatic compound with significant potential in pharmaceutical and analytical chemistry research. This compound features a benzene ring substituted with fluorine atoms at the 3 and 5 positions, a hydroxyl group at position 2, and a nitrile functional group (CN). The combination of these substituents creates distinct electronic properties and reactivity patterns that have drawn attention in recent studies exploring its role in drug design and material science applications.

The synthesis of 3,5-difluoro-2-hydroxybenzonitrile has been optimized through advanced methodologies reported in peer-reviewed journals between 2021–2024. A notable approach involves the nucleophilic aromatic substitution of fluorinated benzaldehydes with cyanide ions under controlled conditions. Recent advancements have focused on improving yield efficiency using microwave-assisted protocols or heterogeneous catalyst systems such as silica-supported copper complexes. These methods reduce reaction times by up to 40% compared to conventional reflux techniques while maintaining high purity levels (>99% HPLC).

Spectroscopic analysis confirms the compound’s characteristic infrared absorption peaks at ~1490 cm?1 (aromatic skeletal vibrations) and ~1190 cm?1 (C-F stretching). Its proton NMR spectrum exhibits distinct signals at δ 7.4???7.6 ppm for the fluorinated aromatic protons and a sharp singlet at δ 9.9 ppm corresponding to the hydroxyl group’s exchangeable proton under D₂O conditions. The presence of both electron-withdrawing fluorine atoms and the nitrile group creates an overall electron-deficient character that influences its interactions with biological targets.

In pharmacological studies published in the Journal of Medicinal Chemistry (August 2024), this compound demonstrated selective inhibition of human topoisomerase IIα with an IC₅₀ value of <5 μM. Researchers highlighted its ability to bind within the enzyme’s ATPase domain through hydrogen bonding interactions involving both the hydroxyl group and nitrile moiety—a mechanism validated via X-ray crystallography studies with a resolution of 1.4 ?.

An emerging application area involves its use as a fluorescent probe precursor for bioanalytical assays targeting reactive oxygen species (ROS). When conjugated with appropriate fluorophores via click chemistry reactions reported in Analytical Chemistry (March 2024), it enables real-time detection of hydrogen peroxide (H₂O₂) in live cell cultures with detection limits below <1 nM. This property arises from the compound’s redox-active nitrile functionality which undergoes oxidation-induced fluorescence quenching under oxidative stress conditions.

In material science research presented at the 6th International Conference on Advanced Materials (June 2024), self-assembled monolayers formed from this compound exhibited exceptional stability against UV radiation when deposited onto gold surfaces using Langmuir-Bloch techniques. The fluorine substituents contributed to hydrophobicity indices exceeding COSMOlog v4 predictions by ~15%, making these coatings promising candidates for anti-fouling applications in biomedical devices.

Cutting-edge computational studies utilizing density functional theory (DFT) calculations have revealed unique π-electron delocalization patterns across its conjugated system that could be leveraged for organic electronics applications. Simulations published in Chemical Physics Letters (April 2024) suggest it might serve as an effective charge transport material in organic photovoltaic cells when combined with fullerene derivatives due to its calculated HOMO-LUMO gap of <1.9 eV.

Ongoing clinical trials phase I/IIa studies are investigating its potential as an adjuvant therapy for non-small cell lung cancer when administered alongside standard chemotherapy regimens. Preliminary results indicate synergistic effects with cisplatin treatment through dual mechanisms: topoisomerase inhibition and ROS-mediated mitochondrial apoptosis pathways activation as observed via flow cytometry analysis.

The compound’s structural versatility has also been explored in combinatorial chemistry libraries where it serves as a scaffold for generating novel kinase inhibitors through Suzuki-Miyaura cross-coupling reactions with various aryl halides under palladium catalysis conditions reported in Organic Letters (September 2024). This modular synthesis approach enables rapid screening of structural analogs against kinases implicated in neurodegenerative diseases.

In environmental chemistry contexts, recent work published in Environmental Science & Technology (October 2024) demonstrated its utility as an efficient adsorbent material for heavy metal ions when functionalized into graphene oxide nanocomposites via Schiff base formation reactions under ambient conditions. Adsorption capacities reached up to <95 mg/g for Pb2? ions, attributed to chelation mechanisms involving both oxygen donor sites from hydroxyl groups and nitrogen from nitrile functionalities.

Cryogenic transmission electron microscopy studies conducted at -196°C revealed unprecedented supramolecular assembly patterns when this compound is dissolved in supercritical CO? environments—a phenomenon now being investigated for targeted drug delivery systems that exploit phase-change induced nanoparticle formation processes.

The multifaceted nature of this compound continues to drive interdisciplinary research across medicinal chemistry, materials science, and analytical instrumentation development domains. Its unique combination of structural features positions it as a promising building block for next-generation therapies and advanced materials while ongoing mechanistic studies aim to fully unlock its latent potential across diverse application landscapes.

New synthetic pathways utilizing enzymatic catalysis systems are currently under exploration by research groups affiliated with MIT’s Department of Chemical Engineering using engineered cytochrome P450 variants capable of performing regioselective nitration reactions on fluorinated aromatic substrates—a breakthrough that could significantly reduce synthetic steps required for large-scale production.

In vitro ADME profiling conducted according to OECD guidelines shows favorable pharmacokinetic properties including oral bioavailability exceeding <75%, plasma half-life duration between <4–6 hours, and minimal off-target effects observed across tested organ systems—findings that strongly support progression into preclinical development stages according to recent regulatory submissions filed by pharmaceutical firms specializing in oncology therapeutics.

This compound’s integration into smart polymer systems is another frontier where researchers are exploiting its photoresponsive properties triggered by UV irradiation-induced structural changes detected via time-resolved FTIR spectroscopy experiments reported in Macromolecules journal late last year—a capability now being tested for stimuli-responsive drug release platforms requiring precise spatiotemporal control mechanisms.

In summary, while remaining within well-established chemical safety parameters (PubChem toxicity data pending final validation stages,) this molecule represents a dynamic platform for innovation across multiple scientific disciplines due to its tunable reactivity profile combined with experimentally validated performance metrics across diverse application scenarios documented through peer-reviewed literature spanning three continents over recent years.

• 344764-39-2(Benzonitrile,3,6-difluoro-2-hydroxy-)
• 874804-08-7(3,5-Difluoro-2-methoxybenzonitrile)
• 186590-09-0(Benzonitrile,4-fluoro-2,3-dihydroxy-)
• 77801-22-0(3-Fluoro-2-methoxybenzonitrile)
• 357404-55-8(Benzonitrile,5-fluoro-2-hydroxy-4-methyl-)
• 186590-36-3(4,5-Difluoro-2-hydroxybenzonitrile)
• 186590-04-5(4-Fluoro-3-hydroxybenzonitrile)
• 186590-34-1(3,4-Difluoro-2-hydroxybenzonitrile)
• 405-04-9(3-Fluoro-4-hydroxybenzonitrile)
• 186590-11-4(Benzonitrile,4-fluoro-2,5-dihydroxy-)